Abstract 2152P
Background
The Gustave Roussy Immune Score (GRIm-Score) was first used in 2017 as a prognostic index. Since the immune pathways in the pathogenesis of HCC has been demonstrated, it was aimed to examine the relationship between GRIm-score and patient survival, treatment side effects and the frequency of hospitalization in HCC patients.
Methods
In between 2010-2021, 108 patients with metastatic or unresectable HCC in our center were screened. Patients receiving sorafenib therapy and ecog 0-1 were included. Clinicopathological data, GRIm scores prior to the sorafenib treatment, previous treatment modalities of patients, hematological side effects of sorafenib, and hospitalizations to the oncology inpatient ward, excluding hospitalizations for planned procedure or chemotherapy, were recorded retrospectively. For the GRIM-Score, patients with NLR > 4.8, LDH > upper limit of normal, or albumin < 3.5 g/dL were given 1 point. Patients were divided in two groups according to the GRIM-Score as low and high.
Results
Sixty four patients were included in the study. Median age was 65 and 95.3% of the patients were male. 79.7% of them had chronic hepatitis. Most of the patients (68%) performed previous local ablative therapy. Low GRIM score (0-1) was demonstrated 60.9% of patients, whereas 39.1% of them had high score(2-3). Hematological side effects and/or AST elevation were observed in 32% of the patients. Hematological side effects were seen in 23% of all patients. During the follow-up period, 75.2% of the patients were hospitalized at least once. 72% of hospitalizations were for supportive treatment. The median number of hospitalizations was 1. The median OS was 5 months. The median survival in the low and high GRIm-score group was 8.8 and 2.7 months respectively (p<0.0001). Hospitalization requirement was found to be significantly higher in the high-GRIm score group compared to low GRIm-score group (p: 0.017). There was no significant difference between the presence of side effects and the GRIm-score group (p: 0.664).
Conclusions
The GRIm-score at the beginning of sorafenib therapy can be used as a significant marker both to determine survival and to predict the need for supportive care in metastatic/unresectable HCC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2140P - Short-term quality-of-life after metastases-directed SBRT: Results of the prospective ESTRO & EORTC OligoCare cohort
Presenter: Daniela Greto
Session: Poster session 07
2141P - Symptom burden and health-related quality of life (HRQoL) in platinum-resistant or -refractory ovarian cancer (PROC): A systematic literature review (SLR)
Presenter: Nikhila Indukuri
Session: Poster session 07
2142P - Criteria for the choice of therapeutic ceiling in the hospitalized oncology patient: Healthcare impact of the multidisciplinary committee with the Intensive Care Unit (ICU)
Presenter: María Esperanza Guirao García
Session: Poster session 07
2143P - Mortality within 30 days after last dose of intravenous systemic anti-cancer therapy: Single-center, one-year, retrospective analysis
Presenter: Osman Sutcuoglu
Session: Poster session 07
2144P - The PRognostic Oncologic Plantology (PROP) website tool predicts 30-day mortality in hospitalized cancer patients on treatment
Presenter: Oriol Mirallas
Session: Poster session 07
2145P - Thromboembolic disease associated with cyclin-dependent kinase inhibitors in patients with breast cancer
Presenter: Javier López Robles
Session: Poster session 07
2146P - Cancer-associated thrombosis clinic: Experience of the Medical Oncology Department of a hospital in Spain
Presenter: Laura Ortega Morán
Session: Poster session 07
2147P - Thrombotic recurrence and bleeding complications in non-small cell lung carcinoma (NSCLC) patients with venous thromboembolism (VTE)
Presenter: Irene Gonzalez Caraballo
Session: Poster session 07
2148P - Venous thromboembolism (VTE) in patients with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitors
Presenter: Lorenzo Gervaso
Session: Poster session 07
2149P - Catheter-related thrombosis in cancer patients: Data from the registry of thrombosis and neoplasia of SEOM (TESEO)
Presenter: Francisco Pelegrín Mateo
Session: Poster session 07